Tag: Watchman FLX
AHA 2024: OPTION trial reports positive outcomes for Watchman FLX at...
Three-year results from the OPTION clinical trial, comparing the Watchman FLX (Boston Scientific) left atrial appendage closure (LAAC) system to oral anticoagulation for stroke...
Medtech insight: Trial pipeline underpins growth strategy for Watchman LAAC device
Investment in a programme of clinical trials will underpin Boston Scientific’s strategy to expand the uptake of its Watchman left atrial appendage closure (LAAC)...
CRT 2022: SURPASS registry shows low rate of adverse events associated...
Results from a new analysis assessing real-world outcomes with the Watchman FLX (Boston Scientific) left atrial appendage closure (LAAC) demonstrated a low rate of...
Next-generation Watchman LAAC device gains US FDA approval
Boston Scientific has received US Food and Drug Administration (FDA) approval for the Watchman FLX left atrial appendage closure (LAAC) device. The device is...